Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Peritoneal Mesothelioma
NCT05041062Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Dec 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in peritoneal mesothelioma, sponsored by University of Chicago. Primary endpoint: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery at 24 months. Started Dec 2021; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on NCT05041062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041062.